Stocks making the biggest moves after hours: ServiceTitan, Mission Produce, Chime Financial and more

After-hours trading was mixed, led lower by ServiceTitan (-19%) on slightly soft current-quarter revenue guidance, Casey's (-10%) despite a fiscal Q1 beat, and Braze (nearly -10%) after guiding non-GAAP EPS to $0.13-$0.14 versus $0.16 consensus. Chime rose almost 10% on upbeat Q3 and full-year guidance and agreed to acquire Stride Bank for $590 million in cash, while InnovAge gained 11% on strong full-year guidance and Mission Produce added 7.5% after beating fiscal Q3 EPS and revenue expectations.

Analysis

The sharpest signal is not the headline EPS dispersion but the market’s intolerance for forward deceleration in premium-multiple software. TTAN and BRZE now face a 1-3 month de-rating risk if sell-side estimates reset lower: modest guide misses can compress EV/revenue multiples disproportionately when investors had underwritten sustained operating leverage. The relevant read-through is cautiously negative for adjacent application software with elevated expectations—HUBS, CRM, TWLO and ZI—but TTAN’s construction-software exposure is more tied to contractor activity and financing conditions than BRZE’s marketing-spend exposure, making a blanket software short inappropriate.

CASY’s reaction implies investors are focused on the durability and composition of same-store growth rather than backward-looking execution. A lower-margin mix shift toward fuel, tobacco or value-oriented food traffic would leave consensus EBITDA assumptions vulnerable even if revenue holds; this creates a potential relative winner in scaled, more discretionary convenience operators such as ATD or in defensively positioned food retail. Conversely, AVO’s upside should not be extrapolated without confirming realized pricing, crop volumes and Mexico sourcing conditions: avocado earnings are highly exposed to supply normalization, so a beat can reverse quickly over the next harvest cycle.

CHYM’s bank acquisition changes the debate from customer growth to regulatory approval, capital consumption and integration execution. Owning more of the banking stack could improve economics over 6-18 months, but cash deployment reduces strategic flexibility and any delay could leave the stock priced for benefits not yet earned. INNV’s improved outlook can support a near-term rerating, although reimbursement-rate visibility, state enrollment trends and medical-cost control—not a single quarter’s revenue—will determine whether the move survives into the next earnings cycle.

Key Decisions for Investors

• Avoid buying TTAN or BRZE into the initial gap; use a 1-3 month watch for estimate-cut completion and stabilization in billings/RPO commentary. Consider a tactical BRZE short only on failed post-earnings rebounds, with a stop above the pre-guidance trading range; falsify if management raises full-year operating-margin or growth guidance.
• Express the software valuation split through a small pair: short BRZE versus long CRM or HUBS for 1-3 months, provided BRZE continues to show weaker forward EPS revisions. The thesis fails if BRZE’s next-quarter bookings or remaining-performance-obligation growth reaccelerates materially relative to peers.
• Treat CASY weakness as an earnings-quality alert rather than an automatic dip-buy. Reassess after detailed same-store-sales mix and gross-margin disclosure; initiate only if inside-sales growth tracks above the high end of management’s range without merchandise-margin erosion. A sustained cut to FY EBITDA guidance invalidates the long case.
• Keep CHYM on a catalyst watch rather than chase the move: regulatory milestones and disclosure of pro forma capital impact are the gating data. A position becomes more attractive if approval timing is clear and management demonstrates that the acquisition is accretive without reducing growth investment; regulatory resistance or materially higher integration costs would reverse the thesis.
• For INNV, a 3-6 month tactical long is justified only if enrollment and reimbursement assumptions support the raised outlook; use the next guidance update as the validation event. Exit on adverse reimbursement commentary or a miss in medical-cost trends, which would challenge the implied margin recovery.